dextroamphetamine has been researched along with Chemical Dependence in 186 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rating forms could quantify substance use interest in subjects with some drug culture exposure but encountered a floor effect in those without." | 2.76 | The "younger-sibling-at-risk design": a pilot study of adolescents with ADHD and an older sibling with substance use disorder. ( Donovan, SJ; Levin, FR, 2011) |
| "Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity." | 2.75 | Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. ( Chakraborty, B; Manniche, PM; Meier, D; Schoedel, KA; Sellers, EM, 2010) |
| "Adult substance abusers were enrolled in this phase I, randomized, single-centre, double-blind study." | 2.74 | Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. ( Jasinski, DR; Krishnan, S, 2009) |
| "Methylphenidate has potential for abuse because it produces behavioural effects similar to those observed with other abused stimulants, such as d-amphetamine and cocaine." | 2.71 | Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. ( Fillmore, MT; Glaser, PE; Rush, CR; Stoops, WW, 2004) |
| " A secondary goal was to determine the accuracy of Drug Recognition Examiners (DREs) in detecting if subjects were dosed with these drugs." | 2.69 | Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana. ( Crouch, DJ; Heishman, SJ; Singleton, EG, 1998) |
| "Sibutramine (Meridia) is a serotonin and norepinephrine reuptake inhibitor marketed for weight control." | 2.69 | Abuse liability assessment of sibutramine, a novel weight control agent. ( Hopper, JA; Mendel, CM; Schuh, LM; Schuster, CR, 2000) |
| "Sertraline is an effective antidepressant acting as a selective serotonin reuptake inhibitor." | 2.68 | Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. ( Busto, U; Kaplan, HL; Sellers, EM; Zawertailo, LA, 1995) |
| "Eight volunteers with histories of drug abuse participated in two experiments examining the modulation of drug choice by behavioral requirements following drug ingestion." | 2.67 | Modulation of drug reinforcement by behavioral requirements following drug ingestion. ( Griffiths, RR; Kirby, KC; Silverman, K, 1994) |
| "Ephedrine choice was positively associated with current use of marijuana and lower levels of baseline anxiety and hunger, as well as with lower scores on two scales measuring dimensions of the personality trait of harm avoidance." | 2.67 | Factors influencing the reinforcing and subjective effects of ephedrine in humans. ( Chait, LD, 1994) |
| " While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs." | 2.49 | Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013) |
| "Lisdexamfetamine dimesylate (LDX) is a once-daily medication approved by the US Food and Drug Administration for the management of attention-deficit/hyperactivity disorder (ADHD) in children (aged 6-12 years) and adults." | 2.45 | The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. ( Najib, J, 2009) |
| "Psychotherapy is still the mainstay of treatment; however, relapse rates are high." | 2.44 | Pharmacotherapy of methamphetamine addiction: an update. ( Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W, 2008) |
| "Learning and memory processes and drug addiction also share intracellular signaling cascades and are associated with similar changes in synaptic plasticity." | 2.44 | [Memory processes and addiction: involvement of the calcineurin signaling pathway]. ( Biała, G, 2007) |
| "A challenge in drug dependence is to delineate long-term behavioral and neurochemical modifications induced by drugs of abuse." | 2.44 | Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse. ( Tassin, JP, 2008) |
| "Amphetamines evaluated were D- and D,L-amphetamine and methamphetamine." | 2.43 | NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. ( , 2005) |
| "However, current substance abuse precludes use of the drug and former abuse liability and social adjustment problems are relative contraindications." | 2.40 | [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders]. ( Aanonsen, NO, 1999) |
| " We considered two independent studies that used different dosing regimens where subjects completed the drug effects questionnaire at multiple time points post d-amphetamine." | 1.43 | Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiology. ( Cowan, RL; de Wit, H; Kessler, RM; Palmer, AA; Smith, CT; Weafer, J; Zald, DH, 2016) |
| "Diagnoses of SUD and alcohol abuse were obtained from The Danish Psychiatric Central Register." | 1.40 | ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study. ( Dalsgaard, S; Frydenberg, M; Mortensen, PB; Thomsen, PH, 2014) |
| " After acquiring the discrimination, the effects of cocaine (0, 25, 50, 100 and 200 mg) administered alone and in combination with aripiprazole (15 mg) were determined." | 1.37 | Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. ( Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW, 2011) |
| "BP 897 was tested for its ability to support self-administration in rhesus monkeys (0." | 1.31 | The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered. ( Balster, RL; Beardsley, PM; Schwartz, JC; Sokoloff, P, 2001) |
| "Aminorex is a cyclic phenylisopropylamine that has been marketed as an anorectic." | 1.29 | Evaluation of the abuse liability of aminorex. ( Harris, LS; Massey, BW; Patrick, GA; Winger, G; Woolverton, WL, 1994) |
| "(+)-AJ 76 is a presumed preferential dopamine (DA) autoreceptor antagonist which, in previous behavioral investigations, has displayed properties characteristic of both DA agonists and DA antagonists." | 1.29 | Antagonism of cocaine self-administration by the preferential dopamine autoreceptor antagonist, (+)-AJ 76. ( Collins, RJ; Myers, JE; Piercey, MF; Richardson, NR; Roberts, DC; Svensson, K, 1993) |
| "Fluoxetine pretreatment, likewise, reduced responding in non-lesioned rats and had no observable effect in lesioned animals." | 1.27 | The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. ( Leccese, AP; Lyness, WH, 1984) |
| "Nefopam was most frequently identified by subjects as being amphetamine-like, though several measures indicated that nefopam produced some sedation." | 1.27 | A comparative assay of nefopam, morphine and d-amphetamine. ( Jasinski, DR; Preston, KL, 1987) |
| "Bereavement after diagnosing AIDS or other HIV disease, psychological symptoms secondary to brain disease and the social consequences of having AIDS all interact to produce a devastating illness where the patient may be intensely grieving, demented and totally rejected by all of society." | 1.27 | Psychosocial aspects of AIDS. ( Goldmeier, D, 1987) |
| "5 microliter of a d-amphetamine solution dosed at 7." | 1.26 | [Effects of lesions of the anterior raphe nuclei on the self-administration of d-amphetamine in the rat : considerable increase of desire for the poison]. ( Le Moal, M; Simon, H; Stinus, L, 1980) |
| "Hooded rats were injected with physiological saline or d-amphetamine sulfate for 13 days on a schedule designed to mimic patterns of abuse: one injection on days 1-11, two injections on day 12, and three injections on day 13; amphetamine dosage for the first three injections was 3." | 1.26 | Chronic amphetamine: effects on defensive flight in the rat. ( Mollenauer, S; Pipkin, B; Plotnik, R; White, M, 1982) |
| "Real life drug abusers ten to utilize drugs in a cyclic pattern of intermittently increasing doses and then "crashing off" depending on the availability of drugs and psychiatric treatment." | 1.26 | Dopamine receptors hypersensitivity: further confirmation following drug abuse model. ( Flemenbaum, A, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 99 (53.23) | 18.7374 |
| 1990's | 19 (10.22) | 18.2507 |
| 2000's | 40 (21.51) | 29.6817 |
| 2010's | 24 (12.90) | 24.3611 |
| 2020's | 4 (2.15) | 2.80 |
| Authors | Studies |
|---|---|
| Negus, SS | 2 |
| Banks, ML | 1 |
| McNealy, KR | 1 |
| Houser, SD | 1 |
| Barrett, ST | 1 |
| Bevins, RA | 1 |
| Langenecker, SA | 1 |
| Kling, LR | 1 |
| Crane, NA | 1 |
| Gorka, SM | 1 |
| Nusslock, R | 1 |
| Damme, KSF | 1 |
| Weafer, J | 2 |
| de Wit, H | 7 |
| Phan, KL | 1 |
| Hoots, JK | 1 |
| Webber, HE | 1 |
| Nunez, C | 1 |
| Cooper, JA | 1 |
| Lopez-Gamundi, P | 1 |
| Lawlor, VM | 1 |
| Lane, SD | 1 |
| Treadway, MT | 1 |
| Wardle, MC | 2 |
| Schrantee, A | 1 |
| Václavů, L | 1 |
| Reneman, L | 1 |
| Verberne, HJ | 1 |
| Booij, J | 1 |
| Tan, HL | 1 |
| Wright, JM | 1 |
| Ren, S | 1 |
| Constantin, A | 1 |
| Clarke, PBS | 1 |
| MacKillop, J | 1 |
| Goldenson, NI | 1 |
| Kirkpatrick, MG | 1 |
| Leventhal, AM | 1 |
| Jackson, C | 1 |
| van Staaden, M | 1 |
| Hudzik, TJ | 1 |
| Basso, A | 1 |
| Boyce-Rustay, JM | 1 |
| Bracken, W | 1 |
| Browman, KE | 1 |
| Drescher, K | 1 |
| Esbenshade, TA | 1 |
| Loberg, LI | 1 |
| Lynch, JJ | 1 |
| Brioni, JD | 1 |
| Toledano, D | 1 |
| Tassin, JP | 3 |
| Gisquet-Verrier, P | 1 |
| Reynolds, AR | 2 |
| Bolin, BL | 2 |
| Stoops, WW | 5 |
| Rush, CR | 6 |
| Dalsgaard, S | 1 |
| Mortensen, PB | 1 |
| Frydenberg, M | 1 |
| Thomsen, PH | 1 |
| Chen, LY | 1 |
| Crum, RM | 1 |
| Strain, EC | 1 |
| Martins, SS | 1 |
| Mojtabai, R | 1 |
| Marcus, BA | 1 |
| Barkla, XM | 1 |
| McArdle, PA | 1 |
| Newbury-Birch, D | 1 |
| Smith, CT | 1 |
| Cowan, RL | 1 |
| Kessler, RM | 1 |
| Palmer, AA | 2 |
| Zald, DH | 1 |
| Eggleston, W | 1 |
| Stork, C | 1 |
| Jasinski, DR | 4 |
| Krishnan, S | 2 |
| Howland, RH | 1 |
| Elkashef, A | 1 |
| Vocci, F | 1 |
| Hanson, G | 1 |
| White, J | 1 |
| Wickes, W | 1 |
| Tiihonen, J | 1 |
| Najib, J | 1 |
| Miranda, F | 1 |
| Jiménez, JC | 1 |
| Cedillo, LN | 1 |
| Sandoval-Sánchez, A | 1 |
| Millán-Mejía, P | 1 |
| Sánchez-Castillo, H | 1 |
| Velázquez-Martínez, DN | 1 |
| McCormick, CG | 1 |
| Henningfield, JE | 3 |
| Haddox, JD | 1 |
| Varughese, S | 1 |
| Lindholm, A | 1 |
| Rosen, S | 1 |
| Wissel, J | 1 |
| Waxman, D | 1 |
| Carter, LP | 1 |
| Seeger, V | 1 |
| Johnson, RE | 1 |
| Hamidovic, A | 2 |
| Childs, E | 2 |
| Conrad, M | 1 |
| King, A | 1 |
| Herin, DV | 1 |
| Grabowski, J | 1 |
| Schoedel, KA | 1 |
| Meier, D | 1 |
| Chakraborty, B | 1 |
| Manniche, PM | 1 |
| Sellers, EM | 2 |
| Lile, JA | 2 |
| Glaser, PE | 3 |
| Hays, LR | 1 |
| Dlugos, AM | 1 |
| Hodgkinson, C | 1 |
| Shen, PH | 1 |
| Goldman, D | 1 |
| Steinkellner, T | 1 |
| Freissmuth, M | 1 |
| Sitte, HH | 1 |
| Montgomery, T | 1 |
| Donovan, SJ | 1 |
| Levin, FR | 1 |
| Estrada, A | 1 |
| Kelley, AM | 1 |
| Webb, CM | 1 |
| Athy, JR | 1 |
| Crowley, JS | 1 |
| Frölich, J | 1 |
| Banaschewski, T | 2 |
| Spanagel, R | 1 |
| Döpfner, M | 1 |
| Lehmkuhl, G | 1 |
| Cortese, S | 1 |
| Holtmann, M | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Dittmann, RW | 1 |
| Graham, J | 1 |
| Taylor, E | 1 |
| Sergeant, J | 1 |
| Kulcsar, IS | 1 |
| Saiz Ruiz, J | 1 |
| Saiz González, D | 1 |
| Antón Fructuoso, P | 1 |
| Adriani, W | 1 |
| Laviola, G | 1 |
| BACHRICH, PR | 1 |
| DAVIDSON, HA | 1 |
| PROUT, CT | 1 |
| OSWALD, I | 1 |
| THACORE, VR | 1 |
| ARTHUR, RJ | 1 |
| Kollins, SH | 1 |
| Tancer, M | 1 |
| Johanson, CE | 12 |
| Gordon, SM | 1 |
| Tulak, F | 1 |
| Troncale, J | 1 |
| Odum, AL | 1 |
| Shahan, TA | 1 |
| Morley, KC | 1 |
| Cornish, JL | 1 |
| Li, KM | 1 |
| McGregor, IS | 1 |
| Gasior, M | 1 |
| Bergman, J | 1 |
| Kallman, MJ | 1 |
| Paronis, CA | 1 |
| Fillmore, MT | 1 |
| McCabe, SE | 1 |
| Knight, JR | 1 |
| Teter, CJ | 1 |
| Wechsler, H | 1 |
| Biala, G | 1 |
| Betancur, C | 1 |
| Mansuy, IM | 1 |
| Giros, B | 1 |
| Yasar, S | 1 |
| Gaál, J | 1 |
| Panlilio, LV | 1 |
| Justinova, Z | 1 |
| Molnár, SV | 1 |
| Redhi, GH | 1 |
| Schindler, CW | 1 |
| Ninkovic, J | 1 |
| Bally-Cuif, L | 1 |
| Dommett, EJ | 1 |
| Simpson, J | 1 |
| Clark, D | 1 |
| Overton, PG | 1 |
| Greenhill, LL | 1 |
| Kliethermes, CL | 1 |
| Kamens, HM | 1 |
| Crabbe, JC | 2 |
| Mello, NK | 1 |
| Wu, LT | 1 |
| Pilowsky, DJ | 1 |
| Schlenger, WE | 1 |
| Galvin, DM | 1 |
| Biała, G | 1 |
| Elia, J | 1 |
| Easley, C | 1 |
| Kirkpatrick, P | 1 |
| Novak, SP | 1 |
| Kroutil, LA | 1 |
| Williams, RL | 1 |
| Van Brunt, DL | 1 |
| Faraone, SV | 1 |
| Upadhyaya, HP | 1 |
| Takahashi, RN | 1 |
| Singer, G | 1 |
| Kalix, P | 1 |
| Griffith, JD | 2 |
| Carranza, J | 1 |
| Griffith, C | 1 |
| Miller, LL | 1 |
| Miller, L | 1 |
| Griffith, J | 1 |
| Kilgore, K | 2 |
| Uhlenhuth, EH | 8 |
| Shuster, L | 2 |
| Leccese, AP | 1 |
| Lyness, WH | 1 |
| Clampit, MK | 1 |
| Pirkle, JB | 1 |
| Glowa, JR | 1 |
| Barrett, JE | 2 |
| Carroll, ME | 2 |
| Stotz, DC | 1 |
| Simon, H | 3 |
| Stinus, L | 2 |
| Le Moal, M | 3 |
| Bradford, LD | 1 |
| Griffiths, RR | 4 |
| Kobasa, SC | 1 |
| Thompson, T | 2 |
| Mollenauer, S | 1 |
| White, M | 1 |
| Plotnik, R | 1 |
| Pipkin, B | 1 |
| Fischman, MW | 3 |
| Schuster, CR | 3 |
| D'Souza, T | 1 |
| Shraberg, D | 1 |
| Cahill, DW | 1 |
| Knipp, H | 1 |
| Mosser, J | 1 |
| Schiff, SR | 1 |
| Shannon, HE | 1 |
| Degregorio, CM | 1 |
| Lamb, RJ | 2 |
| Zawertailo, LA | 1 |
| Busto, U | 1 |
| Kaplan, HL | 1 |
| Silverman, K | 1 |
| Kirby, KC | 1 |
| Chait, LD | 3 |
| Woolverton, WL | 3 |
| Massey, BW | 1 |
| Winger, G | 2 |
| Patrick, GA | 1 |
| Harris, LS | 1 |
| Ellison, G | 1 |
| Switzer, RC | 1 |
| Richardson, NR | 1 |
| Piercey, MF | 1 |
| Svensson, K | 1 |
| Collins, RJ | 1 |
| Myers, JE | 1 |
| Roberts, DC | 1 |
| Block, RW | 1 |
| Lac, ST | 1 |
| Koob, GF | 2 |
| France, CP | 1 |
| Gerak, LR | 1 |
| Rowlett, JK | 1 |
| Woods, JH | 1 |
| Heishman, SJ | 1 |
| Singleton, EG | 1 |
| Crouch, DJ | 1 |
| Heyne, A | 1 |
| Wolffgramm, J | 1 |
| Aanonsen, NO | 1 |
| Schuh, LM | 1 |
| Hopper, JA | 1 |
| Mendel, CM | 1 |
| Homsi, J | 1 |
| Walsh, D | 1 |
| Nelson, KA | 1 |
| Solbrig, MV | 1 |
| Parsons, LH | 1 |
| Kadota, T | 1 |
| Horscroft, N | 1 |
| Briese, T | 1 |
| Lipkin, WI | 1 |
| Di Ciano, P | 1 |
| Blaha, CD | 1 |
| Phillips, AG | 1 |
| Beardsley, PM | 1 |
| Sokoloff, P | 1 |
| Balster, RL | 2 |
| Schwartz, JC | 1 |
| Drouin, C | 1 |
| Darracq, L | 1 |
| Trovero, F | 1 |
| Blanc, G | 1 |
| Glowinski, J | 1 |
| Cotecchia, S | 1 |
| Brady, JV | 1 |
| Snell, JD | 1 |
| Bigelow, GE | 1 |
| Liebson, I | 1 |
| Kaliszak, J | 1 |
| Cole, SO | 1 |
| Götestam, KG | 1 |
| Flemenbaum, A | 3 |
| Carlin, AS | 1 |
| Stauss, FF | 1 |
| Adams, KM | 1 |
| Grant, I | 1 |
| Altshuler, H | 1 |
| Weaver, S | 1 |
| Phillips, P | 1 |
| Guerrant, GO | 1 |
| Hall, CT | 1 |
| Wright, CB | 1 |
| Lamoy, RE | 1 |
| Hobson, RW | 1 |
| Ksir, C | 1 |
| Levee, JR | 1 |
| Cohen, MJ | 1 |
| Rickles, WH | 1 |
| Oviasu, VO | 1 |
| Allen, RP | 1 |
| Safer, D | 1 |
| Covi, L | 1 |
| Pickens, R | 1 |
| Webster, GW | 1 |
| Yu, G | 1 |
| Goudie, AJ | 1 |
| Thornton, EW | 1 |
| Nader, MA | 1 |
| Tatham, TA | 1 |
| Phillips, TJ | 1 |
| Burkhart-Kasch, S | 1 |
| Gwiazdon, CC | 1 |
| Foltin, RW | 2 |
| Kelly, TH | 1 |
| Sherman, JP | 1 |
| Leong, GB | 1 |
| Shaner, AL | 1 |
| Silva, JA | 1 |
| Piazza, PV | 1 |
| Deminière, JM | 1 |
| de la Garza, R | 2 |
| Preston, KL | 2 |
| Corwin, RL | 1 |
| Goldmeier, D | 1 |
| Kornetsky, C | 1 |
| Kato, S | 1 |
| Bailey, DN | 1 |
| Jatlow, PI | 1 |
| Bewley, T | 1 |
| Jarvis, JF | 1 |
| Hoffmeister, F | 2 |
| Goldberg, SR | 2 |
| Schlichting, U | 1 |
| Wuttke, W | 1 |
| Newell, GR | 1 |
| Henderson, BE | 1 |
| Najjar, FB | 1 |
| Bridi, G | 1 |
| Rizk, G | 1 |
| Eisenberg, L | 1 |
| Cavanaugh, J | 1 |
| Held, J | 1 |
| Oates, JA | 1 |
| Forman, MA | 1 |
| Hetznecker, W | 1 |
| Campbell, H | 2 |
| Cline, W | 2 |
| Evans, M | 2 |
| Lloyd, J | 2 |
| Peck, AW | 2 |
| Omenn, GS | 1 |
| Geller, I | 1 |
| Hartmann, RJ | 1 |
| Blum, K | 1 |
| Davis, WM | 1 |
| Smith, SG | 1 |
| Chapple, PA | 1 |
| Choulis, NH | 1 |
| Pugliese, AC | 1 |
| Sever, PS | 1 |
| Caldwell, J | 1 |
| Dring, LG | 1 |
| Williams, RT | 1 |
| Klein, DF | 1 |
| Puri, SK | 1 |
| Lal, H | 1 |
| Sproule, BC | 1 |
| Pahnke, WN | 1 |
| Ellinwood, EH | 1 |
| Cohen, S | 1 |
| Deneau, G | 1 |
| Yanagita, T | 1 |
| Seevers, MH | 1 |
| Ferris, GN | 1 |
| Linn, LS | 1 |
| Frings, CS | 1 |
| Queen, C | 1 |
| Foster, LB | 1 |
| Todd, J | 1 |
| Stoffer, SS | 1 |
| Sapira, JD | 1 |
| Tweeddale, DN | 1 |
| Meketon, BF | 1 |
| Lancaster, B | 1 |
| Rockley, GJ | 1 |
| Spark, D | 1 |
| Papp, P | 1 |
| Goodman, SJ | 1 |
| Becker, DP | 1 |
| Morgan, LK | 1 |
| Sours, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Preliminary Investigation of Individual Differences in Subjective Responses to D-amphetamine, Alcohol, and Delta-9-tetrahydrocannabinol[NCT02485158] | 28 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Premenstrual Hormonal and Affective State Evaluation (PHASE) Project[NCT03862469] | 120 participants (Anticipated) | Interventional | 2019-09-26 | Recruiting | |||
| Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323] | 80 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Hypomania, Amphetamine, and Preferences for Sweets[NCT03810703] | Phase 1 | 93 participants (Actual) | Interventional | 2017-02-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 43.92 | 23.79 | 44.92 | 29.38 | 17.5 |
| ALC Placebo Arm | 7.96 | 4.83 | 11.08 | 5.08 | 6.54 |
| AMP Arm | 27.08 | 43.75 | 11.92 | 18.88 | 45.38 |
| AMP Placebo Arm | 11.92 | 7.04 | 13.38 | 5.04 | 3.13 |
| THC Arm | 24.08 | 18 | 19.63 | 21.96 | 9.92 |
| THC Placebo Arm | 7.88 | 8.67 | 8.88 | 4.83 | 9.88 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 30.83 | 21.33 | 40.75 | 20.46 | 12.58 |
| ALC Placebo Arm | 4.63 | 2.42 | 4.29 | 2.13 | 5.04 |
| AMP Arm | 19.79 | 39.5 | 11.25 | 16.33 | 44.08 |
| AMP Placebo Arm | 5.83 | 6.74 | 8.09 | 2.87 | 2.87 |
| THC Arm | 18.63 | 11.71 | 17.79 | 14.75 | 9.38 |
| THC Placebo Arm | 4.63 | 4.96 | 6.42 | 1.96 | 6.21 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 22.21 | 9.04 | 29.5 | 14.13 | 7.0 |
| ALC Placebo Arm | 2.08 | 1.75 | 4.29 | 1.25 | 4.04 |
| AMP Arm | 16.13 | 31.08 | 11.54 | 11.67 | 38.38 |
| AMP Placebo Arm | 3.5 | 2.54 | 4.25 | 1.63 | 2.46 |
| THC Arm | 15.67 | 7.33 | 16.13 | 11.79 | 10.04 |
| THC Placebo Arm | 2.54 | 4.0 | 4.63 | 1.04 | 5.04 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 12.88 | 7.33 | 22.71 | 9.21 | 4.54 |
| ALC Placebo Arm | 0.96 | 0.25 | 1.29 | 0.83 | 3.83 |
| AMP Arm | 11.08 | 18.38 | 8.54 | 6.25 | 32.5 |
| AMP Placebo Arm | 2.17 | 1.96 | 7.46 | 0.33 | 2.25 |
| THC Arm | 5.79 | 4.88 | 6.83 | 4.96 | 8.79 |
| THC Placebo Arm | 1.08 | 4.38 | 4.54 | 0.42 | 6.17 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 12.83 | 18.67 | 11.71 | 8.83 | 13.5 |
| ALC Placebo Arm | 9.38 | 10.04 | 11.0 | 5.5 | 3.71 |
| AMP Arm | 4.79 | 16.08 | 4.21 | 3.29 | 14.21 |
| AMP Placebo Arm | 12.17 | 9.0 | 10.71 | 6.96 | 5.63 |
| THC Arm | 11.08 | 11.75 | 12.38 | 10.58 | 6.54 |
| THC Placebo Arm | 4.5 | 9.67 | 0.83 | 3.67 | 11.0 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 76.83 | 45.08 | 43.96 | 50.38 | 24.75 |
| ALC Placebo Arm | 17.83 | 14.38 | 16.68 | 11.5 | 10.0 |
| AMP Arm | 43.42 | 53.88 | 15.71 | 30.5 | 42.17 |
| AMP Placebo Arm | 21.58 | 16.63 | 17.71 | 12.54 | 10.96 |
| THC Arm | 38.25 | 28.75 | 25.63 | 31.75 | 17.46 |
| THC Placebo Arm | 18.63 | 25.29 | 15.79 | 12.96 | 18.96 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| DEQ Feel | DEQ Like | DEQ Dislike | DEQ High | DEQ More | |
| ALC Arm | 61.21 | 29.92 | 50.46 | 41.83 | 25.88 |
| ALC Placebo Arm | 12.75 | 11.38 | 15.33 | 7.25 | 7.71 |
| AMP Arm | 34.92 | 55.67 | 16.54 | 27.92 | 50.21 |
| AMP Placebo Arm | 16.46 | 10.42 | 17.54 | 6.83 | 6.54 |
| THC Arm | 31.54 | 20.08 | 23.25 | 29.21 | 16.54 |
| THC Placebo Arm | 13.17 | 13.25 | 15.96 | 7.58 | 12.88 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | -0.33 | -1.13 | 0.79 | -2.04 | 5.46 | 1.08 |
| ALC Placebo Arm | -0.71 | -1.29 | 0.04 | -0.83 | 1.63 | -0.04 |
| AMP Arm | 2.17 | 3.33 | 0.38 | 1.67 | -1.08 | 1.83 |
| AMP Placebo Arm | -0.17 | -0.125 | -0.13 | -1 | 1.71 | 0.25 |
| THC Arm | -0.08 | -0.96 | 1 | -1.54 | 2.88 | 1.42 |
| THC Placebo Arm | -0.04 | -0.08 | -0.08 | -0.38 | 1.08 | 0.17 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | -0.54 | -1.54 | 0.79 | -2.04 | 5.46 | 0.75 |
| ALC Placebo Arm | -0.54 | -1.25 | -0.13 | -0.67 | 1.58 | -0.21 |
| AMP Arm | 2.29 | 2.96 | 0.5 | 1.75 | -1 | 1.54 |
| AMP Placebo Arm | -0.13 | 0.13 | 0.09 | -0.43 | 0.65 | 0.22 |
| THC Arm | -0.17 | -0.96 | 0.58 | -1.29 | 2.58 | 0.83 |
| THC Placebo Arm | -0.08 | -0.08 | -0.17 | -0.42 | 0.79 | 0.08 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | -0.75 | -1.29 | 0.54 | -1.5 | 3.63 | 0.08 |
| ALC Placebo Arm | -0.33 | -1.08 | -0.04 | -0.38 | 0.71 | -0.13 |
| AMP Arm | 1.58 | 1.92 | 0.46 | 1.13 | -0.46 | 1.21 |
| AMP Placebo Arm | -0.04 | 0.33 | 0.04 | -0.33 | 0.21 | 0.13 |
| THC Arm | -0.21 | -0.67 | 0.54 | -1.29 | 2.13 | 0.71 |
| THC Placebo Arm | -0.17 | -0.17 | 0.04 | -0.29 | 0.42 | -0.08 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | -0.71 | -1.17 | 0.33 | -1.25 | 3.17 | 0.08 |
| ALC Placebo Arm | -0.54 | -0.79 | 1.67 | -0.38 | 0.21 | -0.17 |
| AMP Arm | 1.0 | 1.38 | 0.63 | 0.83 | -0.29 | 0.96 |
| AMP Placebo Arm | -0.17 | 0.13 | 0.25 | -0.17 | -0.29 | 0 |
| THC Arm | -0.46 | -0.88 | 0.54 | -0.83 | 1.04 | 0.21 |
| THC Placebo Arm | 0.08 | 0.04 | 0.04 | -0.13 | 0.13 | -0.08 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | 0.25 | -0.29 | 0.33 | -0.75 | 1.29 | 0.83 |
| ALC Placebo Arm | -0.17 | -0.67 | 0.08 | -0.92 | 0.92 | 0.33 |
| AMP Arm | -0.17 | -0.58 | 0.13 | -0.46 | 0.58 | 0.08 |
| AMP Placebo Arm | -0.25 | -0.58 | 0.13 | -1.17 | 1.96 | 0.5 |
| THC Arm | -0.04 | -0.71 | 0.38 | -0.79 | 2.92 | 0.42 |
| THC Placebo Arm | 0.54 | 0.33 | -0.17 | 0.25 | 0.42 | 0.42 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | 1.92 | 1.38 | 2.63 | -0.88 | 3.71 | 3.42 |
| ALC Placebo Arm | -0.33 | -1.17 | 0.29 | -0.96 | 1.54 | 0.29 |
| AMP Arm | 2.88 | 3.71 | 1.13 | 1.63 | -1 | 3.21 |
| AMP Placebo Arm | 0 | 0 | 0.33 | -0.83 | 2.25 | 0.42 |
| THC Arm | 0.17 | -0.54 | 1.54 | -1.38 | 2.96 | 2.04 |
| THC Placebo Arm | 0.71 | 0.88 | 0.13 | 0.04 | 1.13 | 0.96 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| ARC A | ARC MBG | ARC LSD | ARC BG | ARC PCAG | ARC M | |
| ALC Arm | 0.29 | -0.38 | 1.79 | -2.54 | 6.21 | 2.25 |
| ALC Placebo Arm | -0.58 | -1.29 | 0.29 | -1.13 | 1.92 | 0.13 |
| AMP Arm | 2.96 | 3.67 | 1.08 | 2.17 | -1.21 | 2.63 |
| AMP Placebo Arm | -0.33 | -0.29 | -0.04 | -1.29 | 2.67 | 0.42 |
| THC Arm | 0 | -0.83 | 1.42 | -1.71 | 3.54 | 2.04 |
| THC Placebo Arm | -0.08 | -0.13 | 0.08 | -0.67 | 1.58 | 0.29 |
"Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: Feel Drug, Feel High, Like Drug, and Want More. All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome." (NCT03810703)
Timeframe: End of study (Baseline - time 0 and approximately 4 weeks later)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Feel | Like | Dislike | High | More | |
| Amphetamine 10 mg Arm | 35.25 | 50.69 | 27.19 | 24.88 | 45.38 |
| Amphetamine 20 mg Arm | 45.75 | 52.81 | 16.25 | 32.69 | 52.44 |
| Placebo Arm | 18.88 | 37.44 | 19.00 | 17.50 | 29.19 |
28 reviews available for dextroamphetamine and Chemical Dependence
| Article | Year |
|---|---|
Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Alcohol Drinking; Atomoxetine Hydrochloride; Attention Def | 2015 |
Generation Z: Adolescent Xenobiotic Abuse in the 21st Century.
Topics: Adolescent; Amphetamine-Related Disorders; Cannabinoids; Central Nervous System Stimulants; Designer | 2015 |
Lisdexamfetamine: a prodrug stimulant for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Dextroamphetamine; Double-Blind M | 2008 |
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; | 2008 |
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clin | 2009 |
Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies.
Topics: Animals; Behavior Therapy; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Clini | 2010 |
The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.
Topics: Amphetamines; Animals; Dextroamphetamine; Humans; Methamphetamine; Mitochondria; Molecular Structure | 2011 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2013 |
Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimula | 2003 |
NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervo | 2005 |
The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse.
Topics: Animals; Behavior, Addictive; Conditioning, Psychological; Dextroamphetamine; Disease Models, Animal | 2006 |
The science of stimulant abuse.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; De | 2006 |
[Memory processes and addiction: involvement of the calcineurin signaling pathway].
Topics: Animals; Behavior, Addictive; Calcineurin; Dextroamphetamine; Down-Regulation; Hippocampus; Humans; | 2007 |
Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse.
Topics: Animals; Behavior; Central Nervous System Stimulants; Cyclohexanols; Dextroamphetamine; Dopamine; Hu | 2008 |
The pharmacology of khat.
Topics: Alkaloids; Animals; Catha; Dextroamphetamine; Female; Humans; Male; Mice; Motor Activity; Phenylprop | 1984 |
Genetic determinants of responses to drugs of abuse: an evaluation of research strategies.
Topics: Animals; Behavior, Animal; Breeding; Chemical and Drug Induced Liver Injury; Cocaine; Corpus Striatu | 1984 |
Behavioral mechanisms and loci of drug dependence: an overview.
Topics: Animals; Behavior; Compulsive Behavior; Dextroamphetamine; Disease Models, Animal; Humans; Motivatio | 1981 |
Circuits, drugs, and drug addiction.
Topics: Amygdala; Animals; Benzazepines; Brain; Cocaine; Dextroamphetamine; Dopamine; gamma-Aminobutyric Aci | 1998 |
[Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dext | 1999 |
Psychostimulants in supportive care.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Child; Dextroamphetamine; Ephedrine; Humans; Men | 2000 |
The behavioral effects of phencyclidine in animals.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Drug Interactions; Drug Tolerance; Humans; Motor Activ | 1978 |
Hyperkinetic children: the use of stimulant drugs evaluated.
Topics: Achievement; Animals; Attention; Blood Pressure; Central Nervous System; Dextroamphetamine; Feeding | 1975 |
Effects of psychostimulants on aggression.
Topics: Adolescent; Aggression; Amphetamine; Animals; Child; Dextroamphetamine; Dogs; Dose-Response Relation | 1975 |
An experimental analysis of behavioral factors in drug dependence.
Topics: Administration, Oral; Alcoholism; Amphetamine; Animals; Behavior, Animal; Cannabis; Chlorpromazine; | 1975 |
Behavioral and pharmacological determinants of drug abuse.
Topics: Animals; Columbidae; Conditioning, Classical; Dextroamphetamine; Electroshock; Feeding Behavior; Hum | 1992 |
Child psychiatry.
Topics: Adolescent; Adoption; Child; Child Abuse; Child Behavior Disorders; Child Development; Child Psychia | 1972 |
Genetic issues in the syndrome of minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Diseases in Twins; Female; Humans; | 1973 |
Psychedelic drugs and mystical experience.
Topics: Cognition; Dextroamphetamine; Esthetics; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mysticis | 1969 |
31 trials available for dextroamphetamine and Chemical Dependence
| Article | Year |
|---|---|
Anticipation of monetary reward in amygdala, insula, caudate are predictors of pleasure sensitivity to d-Amphetamine administration.
Topics: Adolescent; Adult; Amygdala; Anticipation, Psychological; Caudate Nucleus; Central Nervous System St | 2020 |
Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation.
Topics: Adult; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationship, Drug; Doubl | 2021 |
Validation of a behavioral economic purchase task for assessing drug abuse liability.
Topics: Administration, Oral; Central Nervous System Stimulants; Dextroamphetamine; Double-Blind Method; Eco | 2019 |
A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial.
Topics: Adult; Dextroamphetamine; Dronabinol; Drug Tolerance; Drug Users; Ethanol; Female; Healthy Volunteer | 2015 |
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
Topics: Central Nervous System Stimulants; Dextroamphetamine; Double-Blind Method; Humans; Injections, Intra | 2009 |
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
Topics: Administration, Oral; Adult; Blood Pressure; Central Nervous System Stimulants; Dextroamphetamine; D | 2009 |
Stress-induced changes in mood and cortisol release predict mood effects of amphetamine.
Topics: Adolescent; Adult; Affect; Anger; Anxiety; Central Nervous System Stimulants; Dextroamphetamine; Dou | 2010 |
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Atomoxetine Hydrochloride; Attention; Biogenic Mon | 2010 |
The "younger-sibling-at-risk design": a pilot study of adolescents with ADHD and an older sibling with substance use disorder.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2011 |
Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots.
Topics: Adult; Aerospace Medicine; Aircraft; Arousal; Benzhydryl Compounds; Central Nervous System Stimulant | 2012 |
Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans.
Topics: Adult; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationship, Drug; Doubl | 2004 |
Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users.
Topics: Adolescent; Adult; Affect; Arousal; Behavior; Caffeine; Central Nervous System Stimulants; Dextroamp | 2006 |
Bupropion: clinical assay for amphetamine-like abuse potential.
Topics: Adult; Animals; Antidepressive Agents; Appetite; Blood Pressure; Bupropion; Dextroamphetamine; Doubl | 1983 |
A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers.
Topics: Adult; Antidepressive Agents; Arousal; Blood Pressure; Body Temperature Regulation; Bupropion; Clini | 1983 |
Assessment of dependence potential of drugs in humans using multiple indices.
Topics: Adult; Dextroamphetamine; Drug Tolerance; Emotions; Female; Humans; Male; Substance-Related Disorder | 1983 |
Drug preference and mood in humans: diazepam.
Topics: Choice Behavior; Dextroamphetamine; Diazepam; Emotions; Female; Humans; Male; Placebos; Substance-Re | 1980 |
Drug preference and mood in humans: d-amphetamine.
Topics: Adult; Choice Behavior; Dextroamphetamine; Emotions; Female; Humans; Male; Placebos; Substance-Relat | 1980 |
Drug preference and mood in humans: preference for d-amphetamine and subject characteristics.
Topics: Adult; Choice Behavior; Dextroamphetamine; Emotions; Humans; Personality; Substance-Related Disorder | 1981 |
Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans.
Topics: 1-Naphthylamine; Adolescent; Adult; Alprazolam; Arousal; Attention; Attitude; Dextroamphetamine; Dou | 1995 |
Modulation of drug reinforcement by behavioral requirements following drug ingestion.
Topics: Adult; Arousal; Behavior; Dextroamphetamine; Double-Blind Method; Environment; Humans; Male; Reinfor | 1994 |
Factors influencing the reinforcing and subjective effects of ephedrine in humans.
Topics: Adolescent; Adult; Affect; Dextroamphetamine; Dose-Response Relationship, Drug; Ephedrine; Euphoria; | 1994 |
Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana.
Topics: Adult; Alprazolam; Automobile Driving; Codeine; Dextroamphetamine; Double-Blind Method; Dronabinol; | 1998 |
Abuse liability assessment of sibutramine, a novel weight control agent.
Topics: Adult; Affect; Appetite Depressants; Blood Pressure; Cyclobutanes; Dextroamphetamine; Double-Blind M | 2000 |
Residential laboratory research: a multidimensional evaluation of the effects of drugs on behavior.
Topics: Adult; Attention; Dextroamphetamine; Feeding Behavior; Humans; Marijuana Smoking; Motivation; Psycho | 1990 |
Reinforcing and subjective effects of several anorectics in normal human volunteers.
Topics: Adult; Affect; Appetite Depressants; Dextroamphetamine; Female; Humans; Male; Substance-Related Diso | 1987 |
Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects.
Topics: Body Temperature; Dextroamphetamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Int | 1986 |
Dextroamphetamine. Evaluation of psychomimetic properties in man.
Topics: Administration, Oral; Adult; Catecholamines; Central Nervous System; Clinical Trials as Topic; Depre | 1972 |
Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts.
Topics: Adolescent; Adult; Amphetamine; Benzyl Compounds; Blood Pressure; Clinical Trials as Topic; Dextroam | 1973 |
Proceedings: Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts.
Topics: Adolescent; Adult; Amphetamine; Behavior; Benzyl Compounds; Blood Pressure; Clinical Trials as Topic | 1972 |
Double-blind trial of anorectic agents.
Topics: Adolescent; Adult; Aged; Amphetamine; Appetite Depressants; Clinical Trials as Topic; Dextroamphetam | 1969 |
Amphetamine abuse.
Topics: Acetylcholinesterase; Aggression; Amphetamine; Animals; Antisocial Personality Disorder; Behavior, A | 1971 |
127 other studies available for dextroamphetamine and Chemical Dependence
| Article | Year |
|---|---|
Confronting the challenge of failed translation in medications development for substance use disorders.
Topics: Analgesics, Opioid; COVID-19; Dextroamphetamine; Dopamine Agonists; Dopamine Antagonists; Drug Devel | 2021 |
Investigating sex differences and the effect of drug exposure order in the sensory reward-enhancing effects of nicotine and d-amphetamine alone and in combination.
Topics: Animals; Conditioning, Operant; Dextroamphetamine; Drug Combinations; Female; Humans; Male; Nicotine | 2022 |
QT prolongation by dexamphetamine: Does experience matter?
Topics: Central Nervous System Stimulants; Dextroamphetamine; Electrocardiography; Female; Humans; Long QT S | 2017 |
Enhancement of a visual reinforcer by D-amphetamine and nicotine in adult rats: relation to habituation and food restriction.
Topics: Animals; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphetamine; Feeding Behavi | 2018 |
Characterization of locomotor response to psychostimulants in the parthenogenetic marbled crayfish (Procambarus fallax forma virginalis): A promising model for studying the neural and molecular mechanisms of drug addiction.
Topics: Animals; Astacoidea; Central Nervous System Stimulants; Dextroamphetamine; Disease Models, Animal; L | 2019 |
Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.
Topics: Animals; Cocaine; Dextroamphetamine; Discrimination Learning; Drug Administration Schedule; Histamin | 2013 |
Traumatic stress in rats induces noradrenergic-dependent long-term behavioral sensitization: role of individual differences and similarities with dependence on drugs of abuse.
Topics: Animals; Behavior, Animal; Clonidine; Dextroamphetamine; Hypothalamo-Hypophyseal System; Male; Motor | 2013 |
Relationship between drug discrimination and ratings of subjective effects: implications for assessing and understanding the abuse potential of D-amphetamine in humans.
Topics: Analysis of Variance; Area Under Curve; Blood Pressure; Central Nervous System Stimulants; Dextroamp | 2013 |
Relationship between oral D-amphetamine self-administration and ratings of subjective effects: do subjective-effects ratings correspond with a progressive-ratio measure of drug-taking behavior?
Topics: Administration, Oral; Adult; Affect; Area Under Curve; Central Nervous System Stimulants; Dextroamph | 2013 |
ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Topics: Adolescent; Adult; Age Factors; Alcoholism; Attention Deficit Disorder with Hyperactivity; Central N | 2014 |
Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users.
Topics: Adolescent; Amphetamines; Analgesics, Opioid; Central Nervous System Stimulants; Child; Cocaine-Rela | 2015 |
Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiology.
Topics: Adult; Behavior, Addictive; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Rela | 2016 |
The GABA-B antagonist 2-hydroxysaclofen reverses the effects of baclofen on the discriminative stimulus effects of D-amphetamine in the conditioned taste aversion procedure.
Topics: Animals; Baclofen; Central Nervous System Stimulants; Conditioning, Psychological; Dextroamphetamine | 2009 |
Case histories in pharmaceutical risk management.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Dextroamphetamine; Drug and Narcotic Contro | 2009 |
Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Behavior; Blood Pressure; Cardiovascular System; Central | 2011 |
OPRM1 gene variants modulate amphetamine-induced euphoria in humans.
Topics: Adolescent; Adult; Alleles; Amphetamine; Blood Pressure; Central Nervous System Stimulants; Chromoso | 2011 |
[The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervo | 2012 |
Dextrose and insulin in addiction.
Topics: Alcohol Withdrawal Delirium; Dextroamphetamine; Drug Therapy, Combination; Glucose; Humans; Insulin; | 1967 |
[Abuse potential of sibutramine].
Topics: Appetite Depressants; Central Nervous System Stimulants; Cyclobutanes; Dextroamphetamine; Female; Hu | 2003 |
Elevated levels of impulsivity and reduced place conditioning with d-amphetamine: two behavioral features of adolescence in mice.
Topics: Adolescent; Adolescent Behavior; Age Factors; Animals; Central Nervous System Stimulants; Conditioni | 2003 |
NEW DRUGS OF ADDICTION?
Topics: Adolescent; Amobarbital; Barbiturates; Behavior, Addictive; Dextroamphetamine; Lysergic Acid Diethyl | 1964 |
CONFESSIONS OF A GOOF BALL ADDICT.
Topics: Alcoholism; Amobarbital; Dextroamphetamine; Psychology; Substance-Related Disorders; Toxicology | 1964 |
REACTIONS TO USE OF AMPHETAMINES AS OBSERVED IN A PSYCHIATRIC HOSPITAL.
Topics: Alcoholism; Amobarbital; Amphetamine; Amphetamines; Barbiturates; Dextroamphetamine; Hospitals, Psyc | 1964 |
AMPHETAMINE AND PHENMETRAZINE ADDICTION. PHYSIOLOGICAL ABNORMALITIES IN THE ABSTINENCE SYNDROME.
Topics: Amobarbital; Amphetamine; Amphetamines; Behavior, Addictive; Dextroamphetamine; Electroencephalograp | 1963 |
THE NAVAL MEDICAL OFFICER AS A PSYCHIATRIC PATIENT.
Topics: Antisocial Personality Disorder; Dextroamphetamine; Humans; Mental Disorders; Military Personnel; Mi | 1965 |
Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.
Topics: Adolescent; Adult; Affect; Cross-Over Studies; Dextroamphetamine; Dopamine Agonists; Female; Halluci | 2003 |
An update on attention deficit disorder.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Ch | 2004 |
Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2004 |
D-Amphetamine reinstates behavior previously maintained by food: importance of context.
Topics: Animals; Appetitive Behavior; Central Nervous System Stimulants; Conditioning, Classical; Dextroamph | 2004 |
Preexposure to MDMA ("Ecstasy") delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats.
Topics: Animals; Behavior, Animal; Brain; Dextroamphetamine; Drug Interactions; Extinction, Psychological; H | 2004 |
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2005 |
Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey.
Topics: Adult; Amphetamines; Central Nervous System Stimulants; Dextroamphetamine; Female; Humans; Male; Met | 2005 |
The reinforcing effects of chronic D-amphetamine and morphine are impaired in a line of memory-deficient mice overexpressing calcineurin.
Topics: Animals; Calcineurin; Conditioning, Psychological; Dextroamphetamine; Drug Administration Schedule; | 2005 |
A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.
Topics: Animals; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphetamine; Dose-Response | 2006 |
A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Dextro | 2006 |
Identification of an excitatory amino acid-mediated component of the ventral tegmental area local field potential response to medial prefrontal cortex stimulation: effect of acute d-amphetamine.
Topics: Animals; Central Nervous System Stimulants; Dextroamphetamine; Electric Stimulation; Excitatory Amin | 2007 |
Drug reward and intake in lines of mice selectively bred for divergent exploration of a hole board apparatus.
Topics: Administration, Oral; Amphetamine-Related Disorders; Animals; Central Nervous System Depressants; Ce | 2007 |
Effects of d-amphetamine and buprenorphine combinations on speedball (cocaine+heroin) self-administration by rhesus monkeys.
Topics: Animals; Behavior, Animal; Buprenorphine; Central Nervous System Stimulants; Cocaine; Dextroamphetam | 2007 |
Misuse of methamphetamine and prescription stimulants among youths and young adults in the community.
Topics: Adolescent; Adult; Alcoholism; Amphetamine-Related Disorders; Central Nervous System Stimulants; Com | 2007 |
Lisdexamfetamine dimesylate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphe | 2007 |
The nonmedical use of prescription ADHD medications: results from a national Internet panel.
Topics: Adolescent; Adult; Alcoholism; Amphetamine-Related Disorders; Appetite Depressants; Attention Defici | 2007 |
The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stim | 2007 |
Cross self-administration of delta 9-tetrahydrocannabinol and D-amphetamine in rats.
Topics: Animals; Dextroamphetamine; Dronabinol; Injections, Intravenous; Male; Rats; Rats, Wistar; Reinforce | 1981 |
The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions.
Topics: 5,7-Dihydroxytryptamine; Animals; Cyproheptadine; Dextroamphetamine; Fluoxetine; Humans; Male; Media | 1984 |
Stimulant medication and the hyperactive adolescent: myths and facts.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Dose-Respon | 1983 |
Drug history modifies the behavioral effects of pentobarbital.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Interactions; H | 1983 |
Oral d-amphetamine and ketamine self-administration by rhesus monkeys: effects of food deprivation.
Topics: Animals; Dextroamphetamine; Food Deprivation; Humans; Ketamine; Macaca mulatta; Male; Phencyclidine; | 1983 |
[Effects of lesions of the anterior raphe nuclei on the self-administration of d-amphetamine in the rat : considerable increase of desire for the poison].
Topics: Animals; Brain Stem; Dextroamphetamine; Humans; Male; Raphe Nuclei; Rats; Self Administration; Subst | 1980 |
Responding maintained by cocaine or d-amphetamine under fixed-interval schedules in baboons.
Topics: Animals; Behavior, Animal; Cocaine; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Admini | 1980 |
Chronic amphetamine: effects on defensive flight in the rat.
Topics: Aggression; Animals; Dextroamphetamine; Escape Reaction; Humans; Male; Motor Activity; Rats; Substan | 1982 |
Drug preferences in humans.
Topics: Adult; Arousal; Dextroamphetamine; Diazepam; Emotions; Fenfluramine; Humans; Reinforcement, Psycholo | 1982 |
Cocaine self-administration in humans.
Topics: Adult; Blood Pressure; Body Temperature; Cocaine; Dextroamphetamine; Emotions; Heart Rate; Humans; R | 1982 |
Intracranial hemorrhage associated with amphetamine use.
Topics: Adolescent; Amphetamine; Cerebral Hemorrhage; Dextroamphetamine; Humans; Male; Substance-Related Dis | 1981 |
Intracranial hemorrhage with amphetamine abuse.
Topics: Adult; Cerebral Hemorrhage; Dextroamphetamine; Humans; Male; Methylphenidate; Substance-Related Diso | 1981 |
Conditioned dopaminergic activity.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Conditioning, Classical; Cues; Dextroamphet | 1982 |
Self-administration of the endogenous trace amines beta-phenylethylamine, N-methyl phenylethylamine and phenylethanolamine in dogs.
Topics: 2-Hydroxyphenethylamine; Animals; Biogenic Amines; Cocaine; Conditioning, Operant; Dextroamphetamine | 1982 |
Human d-amphetamine drug discrimination: methamphetamine and hydromorphone.
Topics: Adult; Dextroamphetamine; Discrimination Learning; Dose-Response Relationship, Drug; Humans; Hydromo | 1994 |
Evaluation of the abuse liability of aminorex.
Topics: Aminorex; Animals; Arousal; Dextroamphetamine; Discrimination Learning; Female; Infusions, Intraveno | 1994 |
Dissimilar patterns of degeneration in brain following four different addictive stimulants.
Topics: Animals; Brain; Cocaine; Dextroamphetamine; Disease Models, Animal; Drug Implants; Methamphetamine; | 1993 |
Antagonism of cocaine self-administration by the preferential dopamine autoreceptor antagonist, (+)-AJ 76.
Topics: Animals; Cocaine; Conditioning, Operant; Dextroamphetamine; Dopamine Antagonists; Dose-Response Rela | 1993 |
Medication for attention-deficit hyperactivity disorder: balancing art and science.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Depression | 1996 |
Acquisition of i.v. amphetamine and cocaine self-administration in rats as a function of dose.
Topics: Animals; Cocaine; Dextroamphetamine; Dose-Response Relationship, Drug; Infusions, Intravenous; Male; | 1997 |
Progress report from the testing program for stimulant and depressant drugs (1996).
Topics: Animals; Central Nervous System Depressants; Central Nervous System Stimulants; Dextroamphetamine; D | 1998 |
The development of addiction to d-amphetamine in an animal model: same principles as for alcohol and opiate.
Topics: Animals; Behavior, Animal; Central Nervous System Depressants; Central Nervous System Stimulants; De | 1998 |
Neurotrophic factor expression after CNS viral injury produces enhanced sensitivity to psychostimulants: potential mechanism for addiction vulnerability.
Topics: Animals; Blotting, Western; Borna Disease; Borna disease virus; Brain; Brain Chemistry; Central Nerv | 2000 |
Changes in dopamine efflux associated with extinction, CS-induced and d-amphetamine-induced reinstatement of drug-seeking behavior by rats.
Topics: Animals; Conditioning, Operant; Dextroamphetamine; Dopamine; Dopamine Uptake Inhibitors; Electrochem | 2001 |
The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered.
Topics: Animals; Cocaine; Conditioning, Operant; Dextroamphetamine; Discrimination, Psychological; Dopamine | 2001 |
Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Animals; Brain; Central Nervous System | 2002 |
Relationship between anorectic and reinforcing properties of appetite suppressant drugs: implications for assessment of abuse liability.
Topics: Animals; Appetite; Appetite Depressants; Chlorphentermine; Cocaine; Dextroamphetamine; Diethylpropio | 1978 |
Therapeutic self-medication as a context for drug abuse research.
Topics: Adult; Body Weight; Dextroamphetamine; Drug Prescriptions; Female; Fenfluramine; Humans; Male; Metha | 1978 |
Drug self-administration in humans.
Topics: Adult; Arousal; Dextroamphetamine; Diazepam; Diethylpropion; Emotions; Female; Humans; Male; Placebo | 1978 |
The discriminative properties of amphetamine analogues tested in self-administering rats under maintained stimulus control.
Topics: Amphetamines; Animals; Conditioning, Operant; Dextroamphetamine; Diethylpropion; Discrimination, Psy | 1977 |
Dopamine receptors hypersensitivity: further confirmation following drug abuse model.
Topics: Amphetamine; Amphetamines; Animals; Dextroamphetamine; Disease Models, Animal; Drug Administration S | 1977 |
Rat dopamine hypersensitivity. I. Effect of age.
Topics: Age Factors; Animals; Dextroamphetamine; Drug Hypersensitivity; Humans; Male; Rats; Receptors, Dopam | 1979 |
Rat dopaminergic hypersensitivity. II. Effects of sex.
Topics: Animals; Apomorphine; Dextroamphetamine; Drug Hypersensitivity; Female; Humans; Male; Rats; Receptor | 1979 |
Increased sensitivity to (+)amphetamine self-administered by rats following meso-cortico-limbic dopamine neurone destruction.
Topics: Animals; Dextroamphetamine; Dopamine; Humans; Male; Neurons; Rats; Receptors, Dopamine; Self Adminis | 1979 |
The prediction of neuropsychological impairment in polydrug abusers.
Topics: Adult; Alcoholism; Cannabis; Dextroamphetamine; Humans; Illicit Drugs; Life Style; Mental Disorders; | 1978 |
Intragastric self-administration of psychoactive drugs by the rhesus monkey.
Topics: Animals; Dextroamphetamine; Disease Models, Animal; Ethanol; Haplorhini; Humans; Macaca mulatta; Met | 1975 |
Drug abuse proficiency testing.
Topics: Barbiturates; Cocaine; Dextroamphetamine; False Negative Reactions; Humans; Illicit Drugs; Laborator | 1977 |
Hemodynamic effects of intra-arterial injection of drugs of abuse.
Topics: Animals; Blood Flow Velocity; Dextroamphetamine; Dextropropoxyphene; Dose-Response Relationship, Dru | 1976 |
Rate dependent drug effects: possible state dependency.
Topics: Animals; Conditioning, Classical; Dextroamphetamine; Humans; Male; Rats; Reinforcement Schedule; Sub | 1976 |
Electromyographic biofeedback for relief of tension in the facial and throat muscles of a woodwind musician.
Topics: Adult; Alcoholism; Biofeedback, Psychology; Dextroamphetamine; Electromyography; Facial Muscles; Hum | 1976 |
Abuse of stimulant drugs in Nigeria.
Topics: Adolescent; Adult; Anxiety; Caffeine; Dextroamphetamine; Drug Synergism; Female; Humans; Male; Niger | 1976 |
Perinatal narcotic addiction in mice: sensitization to morphine stimulation.
Topics: Age Factors; Animals; Animals, Newborn; Cocaine; Cycloheximide; Dextroamphetamine; Dextrorphan; Dose | 1975 |
Effects of drug experience on drug induced conditioned taste aversions: studies with amphetamine and fenfluramine.
Topics: Animals; Avoidance Learning; Body Weight; Choice Behavior; Conditioning, Psychological; Dextroamphet | 1975 |
Locomotor responses of FAST and SLOW mice to several alcohols and drugs of abuse.
Topics: Alcohols; Animals; Caffeine; Dextroamphetamine; Diazepam; Mice; Mice, Inbred Strains; Motor Activity | 1992 |
Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans.
Topics: Appetite Depressants; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationsh | 1991 |
Dexamphetamine for "speed" addiction.
Topics: Adult; Dextroamphetamine; Female; Humans; Male; Methamphetamine; Substance-Related Disorders | 1990 |
Human d-amphetamine drug discrimination: testing with d-amphetamine and hydromorphone.
Topics: Adult; Arousal; Dextroamphetamine; Discrimination Learning; Dose-Response Relationship, Drug; Humans | 1989 |
Narcolepsy, paranoid psychosis, and analeptic abuse.
Topics: Adult; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; Male; Methylphenidate; Middle Ag | 1989 |
Factors that predict individual vulnerability to amphetamine self-administration.
Topics: Animals; Dextroamphetamine; Male; Motor Activity; Rats; Rats, Inbred Strains; Risk Factors; Self Adm | 1989 |
Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys.
Topics: Animals; Anti-Anxiety Agents; Appetite Depressants; Bupropion; Dextroamphetamine; Discrimination Lea | 1987 |
A comparative assay of nefopam, morphine and d-amphetamine.
Topics: Behavior; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; Male; Morphine; Nefopam; Oxaz | 1987 |
The reinforcing properties of amphetamine in overweight subjects and subjects with depression.
Topics: Adult; Affect; Choice Behavior; Depression; Dextroamphetamine; Female; Humans; Male; Obesity; Person | 1987 |
Anorectics: effects on food intake and self-administration in rhesus monkeys.
Topics: Animals; Appetite Depressants; Dextroamphetamine; Eating; Female; Macaca mulatta; Male; Reinforcemen | 1987 |
The effects of food deprivation on the self-administration of psychoactive drugs.
Topics: Animals; Cocaine; Dextroamphetamine; Diazepam; Food Deprivation; Macaca mulatta; Male; Nicotine; Per | 1987 |
Psychosocial aspects of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Attitude to Health; Brain Diseases; Child; Dementia; Dextroamphe | 1987 |
Brain-stimulation reward: a model for the neuronal bases for drug-induced euphoria.
Topics: Animals; Brain; Cocaine; Dextroamphetamine; Electric Stimulation; Euphoria; Humans; Models, Neurolog | 1985 |
[Behavioral changes in rhesus monkeys induced by repeated administration of ephedrine].
Topics: Animals; Behavior, Animal; Dextroamphetamine; Disease Models, Animal; Ephedrine; Humans; Macaca mula | 1985 |
Methaqualone overdose: analytical methodology, and the significance of serum drug concentrations.
Topics: Alcohol Drinking; Alkanes; Chloroform; Chromatography, Gas; Chromatography, Thin Layer; Consciousnes | 1973 |
Heroin and cocaine addiction.
Topics: Adolescent; Adult; Amphetamine; Barbiturates; Cannabis; Cocaine; Dextroamphetamine; Ethanol; Female; | 1965 |
The nasal drop addict.
Topics: Cautery; Chlorpheniramine; Dextroamphetamine; Humans; Methylprednisolone; Nasal Decongestants; Rhini | 1969 |
A comparison of chlorpromazine, imipramine, morphine and d-amphetamine self-administration in cocaine-dependent rhesus monkeys.
Topics: Animals; Behavior, Animal; Chlorpromazine; Cocaine; Dextroamphetamine; Dose-Response Relationship, D | 1973 |
Self-administration of d-amphetamine, morphine and chlorpromazine by cocaine "dependent" rhesus monkeys.
Topics: Animals; Behavior, Animal; Chlorpromazine; Cocaine; Conditioning, Operant; Dextroamphetamine; Extinc | 1970 |
Discussion of case-control study of Hodgkin's disease.
Topics: Amphetamine; Antigens, Viral; Dextroamphetamine; Epidemiologic Methods; Genotype; Herpesvirus 4, Hum | 1974 |
Management of micro-emboli of the digital arteries.
Topics: Adult; Angiography; Arteries; Catheterization; Dextrans; Dextroamphetamine; Embolism; Fingers; Hepar | 1974 |
Symposium: behavior modification by drugs. 3. The clinical use of stimulant drugs in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Feeding and Eat | 1972 |
The effects of low-dose combinations of D-amphetamine and cocaine on experimentally induced conflict in the rat.
Topics: Animals; Behavior, Animal; Cocaine; Conditioning, Psychological; Conflict, Psychological; Dextroamph | 1972 |
Alpha-methyltyrosine to prevent self-administration of morphine and amphetamine.
Topics: Animals; Conditioning, Operant; Dextroamphetamine; Humans; Male; Methyltyrosines; Morphine; Morphine | 1972 |
Amphetamine-type drugs for hyperactive children.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Body Weight; Brain; Child; Dextroamphetamin | 1972 |
Hyperactive children.
Topics: Brain; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Substance-Related Disorders | 1973 |
Separation and quantitation of mixtures of the most commonly abused drugs.
Topics: Amobarbital; Cannabis; Chromatography, Thin Layer; Dextroamphetamine; Ephedrine; Humans; Indicators | 1973 |
The effects of drugs on learning and memory. A review of the literature.
Topics: Aged; Amphetamine; Animals; Cannabis; Child; Chlorpromazine; Dextroamphetamine; Female; Hallucinogen | 1973 |
The metabolism of amphetamine in dependent subjects.
Topics: Biodegradation, Environmental; Carbon Radioisotopes; Chromatography, Paper; Dextroamphetamine; Femal | 1973 |
Letter: Pathophysiology of depressive syndromes.
Topics: Amphetamine; Depression; Dextroamphetamine; Humans; Monoamine Oxidase Inhibitors; Phenethylamines; S | 1974 |
Reduced threshold to pain induced aggression specifically related to morphine dependence.
Topics: Aggression; Animals; Dextroamphetamine; Drug Synergism; Electroshock; Ethanol; Humans; Male; Morphin | 1974 |
Self-administration of psychoactive substances by the monkey.
Topics: Animals; Behavior, Animal; Caffeine; Catheterization; Chlorpromazine; Cocaine; Codeine; Dextroamphet | 1969 |
Addiction to Daprisal.
Topics: Adult; Amobarbital; Aspirin; Depression; Dextroamphetamine; Drug Combinations; Female; Humans; Male; | 1972 |
Physician characteristics and attitudes toward legitimate use of psychotherapeutic drugs.
Topics: Adult; Aged; Attitude; Chlordiazepoxide; Dextroamphetamine; Drug Prescriptions; Ethics, Medical; Fam | 1971 |
Improved colorimetric method for assay of amphetamines in urine.
Topics: Alkaloids; Amphetamine; Azo Compounds; Chemical Phenomena; Chemistry; Chemistry, Clinical; Chlorofor | 1971 |
Lilliputian hallucinatiion complicatign dexamphetamine-amylobarbitone addiction.
Topics: Adolescent; Adult; Barbiturates; Dextroamphetamine; Humans; Introversion, Psychological; Male; Psych | 1968 |
Effect of D-amphetamine on menstruation.
Topics: Animals; Dextroamphetamine; Female; Humans; Menstruation; Substance-Related Disorders | 1969 |
Amphetamine taking among young offenders.
Topics: Adolescent; Amphetamine; Dextroamphetamine; England; Humans; Juvenile Delinquency; Male; Substance-R | 1970 |
Critical incidents in the context of family therapy. Critical incident no. 6.
Topics: Adolescent; Adult; Child; Conflict, Psychological; Depression; Dextroamphetamine; Family Therapy; Fe | 1970 |
Intracranial hemorrhage associated with amphetamine abuse.
Topics: Adolescent; Adult; Amphetamine; Cerebral Hemorrhage; Dextroamphetamine; Humans; Male; Substance-Rela | 1970 |
The epidemiology of drug overdosage.
Topics: Amphetamine; Aspirin; Caffeine; Dextroamphetamine; Drug and Narcotic Control; Female; Humans; Substa | 1970 |
Addiction to daprisal.
Topics: Adult; Amobarbital; Analgesics; Aspirin; Depression; Dextroamphetamine; Humans; Phenacetin; Substanc | 1968 |